- Home
- HNVR vs GNLX Comparison
HNVR vs GNLX Comparison
Compare HNVR & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$2.82
Company Overview
Basic Information| Metric | HNVR | GNLX |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.6M | 124.8M |
| IPO Year | 2022 | 2022 |
Fundamental Metrics
Financial Performance| Metric | HNVR | GNLX |
|---|---|---|
| Price | $21.34 | $2.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $24.50 | $19.75 |
| AVG Volume (30 Days) | 6.0K | ★ 169.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | N/A | ★ 18.10 |
| EPS | ★ 1.00 | N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | $28.03 | N/A |
| Revenue Next Year | $8.02 | N/A |
| P/E Ratio | $21.12 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.31 | $1.99 |
| 52 Week High | $24.36 | $8.54 |
Technical Indicators
Market Signals| Indicator | HNVR | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 35.30 | 52.16 |
| Support Level | $20.44 | $2.31 |
| Resistance Level | $22.53 | $3.05 |
| Average True Range (ATR) | 0.55 | 0.16 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 32.86 | 62.89 |
Price Performance
Historical Comparison HNVR
GNLX
About HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.